Stem cell therapy for cerebral palsy

John Bartley, James Edwin Carroll

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Cerebral palsy is a group of brain diseases which produce chronic motor disability in children. The causes are quite varied and range from abnormalities of brain development to birth-related injuries to postnatal brain injuries. Due to the increased survival of very premature infants, the incidence of cerebral palsy may be increasing. While premature infants and term infants who have suffered neonatal hypoxic-ischaemic (HI) injury represent only a minority of the total cerebral palsy population, this group demonstrates easily identifiable clinical findings, and much of their injury is to oligodendrocytes and the cerebral white matter. While the use of stem cell therapy is promising, there are no controlled trials in humans with cerebral palsy and only a few trials in patients with other neurologic disorders. However, studies in animals with experimentally induced strokes or traumatic injuries have indicated that benefit is possible. The potential to do these transplants via injection into the vasculature rather than directly into the brain increases the likelihood of timely human studies. As a result, variables appropriate to human experiments with intravascular injection of cells, such as cell type, timing of the transplant and effect on function, need to be systematically performed in animal models with HI injury, with the hope of rapidly translating these experiments to human trials.

Original languageEnglish (US)
Pages (from-to)541-549
Number of pages9
JournalExpert Opinion on Biological Therapy
Volume3
Issue number4
DOIs
StatePublished - Jul 1 2003

Fingerprint

Cerebral Palsy
Cell- and Tissue-Based Therapy
Stem cells
Brain
Stem Cells
Transplants
Wounds and Injuries
Premature Infants
Animals
Birth Injuries
Injections
Oligodendroglia
Brain Diseases
Nervous System Diseases
Population Groups
Brain Injuries
Animal Models
Experiments
Stroke
Survival

Keywords

  • Cerebral palsy
  • Embryonic stem cells
  • Marrow stromal cells
  • Neuron
  • Oligodendrocyte
  • Periventricular leukomalacia
  • Stem cells

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Stem cell therapy for cerebral palsy. / Bartley, John; Carroll, James Edwin.

In: Expert Opinion on Biological Therapy, Vol. 3, No. 4, 01.07.2003, p. 541-549.

Research output: Contribution to journalReview article

@article{9a0a4fa8beb9410d8ae91e00a9e148a4,
title = "Stem cell therapy for cerebral palsy",
abstract = "Cerebral palsy is a group of brain diseases which produce chronic motor disability in children. The causes are quite varied and range from abnormalities of brain development to birth-related injuries to postnatal brain injuries. Due to the increased survival of very premature infants, the incidence of cerebral palsy may be increasing. While premature infants and term infants who have suffered neonatal hypoxic-ischaemic (HI) injury represent only a minority of the total cerebral palsy population, this group demonstrates easily identifiable clinical findings, and much of their injury is to oligodendrocytes and the cerebral white matter. While the use of stem cell therapy is promising, there are no controlled trials in humans with cerebral palsy and only a few trials in patients with other neurologic disorders. However, studies in animals with experimentally induced strokes or traumatic injuries have indicated that benefit is possible. The potential to do these transplants via injection into the vasculature rather than directly into the brain increases the likelihood of timely human studies. As a result, variables appropriate to human experiments with intravascular injection of cells, such as cell type, timing of the transplant and effect on function, need to be systematically performed in animal models with HI injury, with the hope of rapidly translating these experiments to human trials.",
keywords = "Cerebral palsy, Embryonic stem cells, Marrow stromal cells, Neuron, Oligodendrocyte, Periventricular leukomalacia, Stem cells",
author = "John Bartley and Carroll, {James Edwin}",
year = "2003",
month = "7",
day = "1",
doi = "10.1517/eobt.3.4.541.21207",
language = "English (US)",
volume = "3",
pages = "541--549",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Stem cell therapy for cerebral palsy

AU - Bartley, John

AU - Carroll, James Edwin

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Cerebral palsy is a group of brain diseases which produce chronic motor disability in children. The causes are quite varied and range from abnormalities of brain development to birth-related injuries to postnatal brain injuries. Due to the increased survival of very premature infants, the incidence of cerebral palsy may be increasing. While premature infants and term infants who have suffered neonatal hypoxic-ischaemic (HI) injury represent only a minority of the total cerebral palsy population, this group demonstrates easily identifiable clinical findings, and much of their injury is to oligodendrocytes and the cerebral white matter. While the use of stem cell therapy is promising, there are no controlled trials in humans with cerebral palsy and only a few trials in patients with other neurologic disorders. However, studies in animals with experimentally induced strokes or traumatic injuries have indicated that benefit is possible. The potential to do these transplants via injection into the vasculature rather than directly into the brain increases the likelihood of timely human studies. As a result, variables appropriate to human experiments with intravascular injection of cells, such as cell type, timing of the transplant and effect on function, need to be systematically performed in animal models with HI injury, with the hope of rapidly translating these experiments to human trials.

AB - Cerebral palsy is a group of brain diseases which produce chronic motor disability in children. The causes are quite varied and range from abnormalities of brain development to birth-related injuries to postnatal brain injuries. Due to the increased survival of very premature infants, the incidence of cerebral palsy may be increasing. While premature infants and term infants who have suffered neonatal hypoxic-ischaemic (HI) injury represent only a minority of the total cerebral palsy population, this group demonstrates easily identifiable clinical findings, and much of their injury is to oligodendrocytes and the cerebral white matter. While the use of stem cell therapy is promising, there are no controlled trials in humans with cerebral palsy and only a few trials in patients with other neurologic disorders. However, studies in animals with experimentally induced strokes or traumatic injuries have indicated that benefit is possible. The potential to do these transplants via injection into the vasculature rather than directly into the brain increases the likelihood of timely human studies. As a result, variables appropriate to human experiments with intravascular injection of cells, such as cell type, timing of the transplant and effect on function, need to be systematically performed in animal models with HI injury, with the hope of rapidly translating these experiments to human trials.

KW - Cerebral palsy

KW - Embryonic stem cells

KW - Marrow stromal cells

KW - Neuron

KW - Oligodendrocyte

KW - Periventricular leukomalacia

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=0037927556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037927556&partnerID=8YFLogxK

U2 - 10.1517/eobt.3.4.541.21207

DO - 10.1517/eobt.3.4.541.21207

M3 - Review article

C2 - 12831360

AN - SCOPUS:0037927556

VL - 3

SP - 541

EP - 549

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 4

ER -